Study: Device industry's business model is unsustainable; A look at how devicemakers donate to politicians;

 @FierceMedDev: Out of the mind of a Ph.D student- a new test for glucose levels using sweat, urine or tears. More | Follow @FierceMedDev

 @MarkHFierce: The FDA wants a judge to dismiss a lawsuit by ex-device center employees accusing the agency of spying on them. Article | Follow @MarkHFierce

 @DamianFierce: Welch Allyn touts its easy-to-use, iPhone-based eye exam device. Story | Follow @DamianFierce

> The medical device industry's business model is outmoded, and devicemakers will need to change their ways to cope with changing markets, according to a study by the Boston Consulting Group. Article

> Mass Device takes a look at how the medical device world targets its campaign contributions, and, unsurprisingly, anti-tax stalwart Sen. Orrin Hatch is the top recipient. Story

> Dutch medical device consulting firm Qserve group is expanding into Massachusetts, which houses one of the largest industry clusters in the United States. Item

> Roche Diagnostics ($RHHBY) has launched its Accu-Chek device in the U.S. The tech combines a blood glucose meter with an insulin pump via Bluetooth wireless technology. More

> Researchers are developing a disposable microchip that could enable easier diagnosis of everything from cancer to sexually transmitted infections. Story

> Rosetta Genomics and Precision Therapeutics have launched the miRview mets2 assay in the U.S. oncology market. Release

Biotech News

 @FierceBiotech: J&J, Lilly and Boehringer tout data on SGLT2 drugs for diabetes. More | Follow @FierceBiotech

 @JohnCFierce: BioInvent in Sweden takes out the ax again and chops 20 jobs, the survivors are focusing on cancer drugs. Release | Follow @JohnCFierce

 @RyanMFierce: Sanofi/Genzyme's late-stage Gaucher pill hits goal in late-stage study, next-gen treatment for rare LSD. More | Follow @RyanMFierce

> J&J, Astellas strike potential $945M deal for oral RA drug. Story

> ArQule shares nosedive with failure of key PhIII trial for lung cancer drug. Article

Pharma News

@FiercePharma: Kaiser, Washington Post team up for look at co-pay coupons. Upshot: Good for patient, but not for payer. More | Follow @FiercePharma

> More payers than expected cover Vivus' Qsymia. Story

> Merck's Gardasil deemed safe in another large study. Report

Pharma Manufacturing News

> Drugs for illegal Internet pharmacy made in India, Mexico. Report

> China's Tianyin moves ahead with plant as profit plummets. Story

> FDA tries to teach consumers of Internet dangers. Article

Biotech Research News

> Study: Impropriety affects retracted research more than honest mistakes. Article

> New drug target could halt age-related immune system declines. Story

> UC Davis: Induced pluripotent stem cells resemble cancer cells. Report

> Avatar mice up ante for personalized drug treatment research. Item